We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Concepta Plc | LSE:CPT | London | Ordinary Share | GB00BYZ2R301 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.98 | 1.90 | 2.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMHC
RNS Number : 0530A
MyHealthChecked PLC
21 September 2022
MyHealthChecked PLC
("MyHealthChecked", "MHC", the "Group" or the "Company")
Half-Year Report
MyHealthChecked PLC, the consumer home-testing healthcare company, announces its unaudited half-year report for the six months ended 30 June 2022, which were stronger than expected and ahead of management expectations.
Financial Highlights
-- Revenue up circa threefold to GBP9.8m (H1 2021: GBP3.3m) * Post-period end: Record breaking July revenues of GBP6.8m (unaudited) -- Adjusted EBITDA improved to GBP0.37m (H1 2021: loss of GBP0.20m) -- Improvement in Gross Profit to GBP1.5m (H1 2021: GBP1.1m) -- Net cash generated from operating activities of GBP0.96m (H1 2021: GBP1.29m utilised) -- Cash balance at period end of GBP7.0m (H1 2021: GBP2.2m) * Whilst continuing to invest across the business for future growth -- Strong cash generation and balances ensure next growth phases are self-funded
Commercial & Operational Highlights
-- Distribution of FlowFlex(TM) COVID-19 lateral flow test kits into top 2 pharmacy retailers -- Over 6.4m COVID lateral flow tests delivered into the market, with a further 5m delivered post-period end -- Launch of new self-funded portfolio DNA tests -- Successful launch of DNA at-home wellness test range on Amazon -- Development technology builds for new blood testing launch in Q4 2022 -- Retailer engagement around new testing portfolio
Penny McCormick, Chief Executive Officer of MyHealthChecked PLC, said : "We have exceeded our expectations for revenue performance in the first half of the year, and have further demonstrated our position of strength which has been earned through strong delivery and consistent customer service, despite even greater COVID unpredictability than experienced in 2021. Cash generation has been a top KPI for us, to ensure that we can self-fund our next growth phases and invest in building great technology and services for a successful and sustainable future. I want to thank each person who has delivered for MHC this year, doing so alongside the work being undertaken as we work towards a new portfolio and associated launches, which we are excited to share with the market in Q4."
Investor presentation
Penny McCormick, Chief Executive Officer and Nicholas Edwards, Chief Financial Officer, will provide a live presentation relating to the Half-Year Report via the Investor Meet Company platform tomorrow (Thursday 22 September 2022) at 4:30pm BST. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation via the link below:
https://www.investormeetcompany.com/myhealthchecked-plc/register-investor
MyHealthChecked PLC www.myhealthcheckedplc.com P enny McCormick , Chief Executive via Walbrook PR Officer Nicholas Edwards, Chief Financial Officer SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550 (NOMAD) Neil Baldwin Oberon Capital Ltd (Broker) Tel: +44 (0)20 3179 5344 Mike Seabrook mikeseabrook@oberoninvestments.com Walbrook PR Ltd (Media Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com & IR) Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests, supported by a user-friendly digital interface.
MyHealthChecked is the umbrella brand of a range of at-home wellness tests that are available online, and will be viable for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at-home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
CHAIRMAN AND CEO JOINT STATEMENT
We are delighted with the delivery of a robust financial performance during the first half of 2022, which has been achieved alongside delivery of our other Company milestones including product and technical development and product launches. Significantly, this included the successful development, build and launch of our new portfolio of DNA wellness test panels, which has been our first milestone launch following the success of our COVID testing portfolio. We have sustained our progress in the COVID space which has become increasingly competitive this year, demonstrating that once again we have nurtured our customer base through high levels of uncertainty and surge demand, with strong execution having added the distribution of lateral flow tests to our "at-home" product portfolio.
This performance has been underpinned by a strong customer base, robust partner suppliers, and most importantly, a committed team who have delivered another superb set of results. Our thanks go to each person who has worked to deliver as part of this team for MHC this year, together we are energised and eager to deliver our new product launches in the coming months.
Financial performance - supply chain management and customer service
We traded strongly through Spring which far exceeded expectations with revenue delivery of GBP9.8m (six months ended 30 June 2021: GBP3.3m; year ended 31 December 2021: GBP16.4m) and an adjusted EBITDA achievement of GBP372,000 (six months ended 30 June 2021: GBP199,000 loss; year ended 31 December 2021: GBP2,729,000). Revenue growth in the period was driven by high volume distribution of COVID lateral flow tests ("LFTs") which were supplied into top pharmacy retailers via both in-store and online channels. Demand spiked in April as direct-to-consumer purchases were driven by the Government's cessation of free lateral flow testing for the general public, and a change in consumer behaviour to 'self-elected' lateral flow testing. Store distribution increased throughout the first half of the year, building a reach that spanned impulse travel outlets through to flagship top-tier city-centre stores.
During the period the business managed a high-volume national supply chain, shipping over 6.4m COVID tests into the market and ensuring that we carefully managed purchasing and logistics in an unpredictable and challenging global situation.
Gross margins have reduced to 15.4% (six months ended 30 June 2021: 33.6%; year ended 31 December 2021: 31.3%) reflecting the change in product mix from higher margin COVID PCR testing to LFTs in what is a competitive, high demand environment, and whilst the margins associated with LFTs are lower than laboratory testing, we have used our best efforts to balance customer value with the promise of a first-class, reliable supply chain management.
Overheads were broadly in line with prior years. In April we took the decision to close our Manchester laboratory operation, reducing future operational costs by approximately GBP25,000 per month. Our lab and experienced staff team played a key role in securing major contracts and servicing customer orders in 2021, and our team delivered during peak demand phases. The closure has enabled the business to focus on the commercialisation and development of our digital platform, and future investment will be channelled into strengthening the areas that provide the greatest long term growth potential, namely our digital platform, complementary services, and commercialisation.
Adjusted EBITDA is calculated as follows:
Unaudited Unaudited Audited 30 June 2022 30 June 2021 31 December 2021 GBP'000 GBP'000 GBP'000 ------------------------------- -------------- -------------- ------------------ Operating profit/(loss) 12 (267) 2,046 Depreciation and amortisation 103 61 157 Impairment provision - - 414 Closure of laboratory costs * 153 - - Share based payments 104 7 112 ------------------------------- -------------- -------------- ------------------ Adjusted EBITDA 372 (199) 2,729 ------------------------------- -------------- -------------- ------------------
* Includes additional depreciation of GBP66,000
As a performance milestone on the acquisition of Nell Health Limited has not been met the Directors believe that the contingent deferred consideration of GBP1m will no longer be payable and have therefore released the provision for this amount. Consequently the Group's profit before and after taxation amounted to GBP1,009,000 (six months ended 30 June 2021: GBP269,000 loss; year ended 31 December 2021: GBP2,004,000) giving a basic earnings per share of 0.13p (six months ended 30 June 2021: 0.04p loss; year ended 31 December 2021: 0.28p) and fully diluted earnings per share of 0.13p (year ended 31 December 2021: 0.27p).
Our careful delivery and focus on expenditure has also enabled us to retain a robust cash position with cash balances as at 30 June 2022 of GBP6,995,000 (six months ended 30 June 2021: GBP2,214,000; year ended 31 December 2021: GBP6,387,000). This marks the achievement of cash KPIs and our commitment to generating income for investment in our future portfolio and rollout.
New product launches
The delivery of our testing portfolio, and subsequent soft launch, has been a significant milestone for us in 2022 as we have begun to build a portfolio of consumer wellness tests to support market needs outside of the pressurised NHS. Our DNA tests have been developed in house, using SNPs ("Single Nucleotide Polymorphisms") that must meet specific criteria before our Scientific Advisory Board approves them for inclusion within our tests, and have been developed to meet an anticipated change in consumer behaviour to self-management and preventative wellness. Our initial portfolio has been priced competitively within the DNA space for accessibility, and whilst it is far too early to comment on market position, our initial launch on Amazon and ongoing retailer discussions have indicated that the market is receptive to at-home wellness testing, including those using DNA extraction methods. We continue to work towards expanding our distribution network for this new portfolio.
Technology Developments
A key development area for us in the first half of this year has been our digital platform, which includes a simple reporting format for our new DNA tests. We are further expanding this to accommodate our upcoming product launches, whilst ensuring risk, customer safety, GDPR, data, security, regulations and governance are at the core of our digital evolution. Our platform has been used directly by well over 100,000 customers and provides a great customer experience that meets with the approval of our direct at-home customers and our retail partners. Our investment and development team continues to channel into the building of a 'growth stack' where the emphasis is on technology that allows for growth and auto scaling as our volume increases, focusing on a modular approach that will ensure our platform is agile, scalable and adaptable to the evolving digital landscape.
Post-period achievements
July 2022 was a record-breaking month with revenue of GBP6.8m (unaudited) after the delivery of over 5.5m COVID LFTs into the market in that month alone. Alongside this delivery we have made significant progress on building a Phase 2 portfolio of further wellness products ready for launch in Q4 2022, which have been market validated using quantitative customer insights. These tests, that predominantly use blood sampling methods, will further strengthen our range, and enable us to provide the most popular tests, and subsequent results on our proven, simple to use digital reporting platform.
Market readiness and new launches
Our team has grown in terms of calibre through the period, with the appointment of digital development expertise, product management and marketing personnel, along with the appointment of additional medical advisors and knowledgeable subject matter experts in key marketing disciplines. We will execute a significant marketing push in line with our new product launches, and look forward to providing an update as we build momentum towards our launches. Much of this strategy is being shaped by further qualitative market insights through Q3 and Q4, as we invest in listening to a customer base that has emerged since the pandemic with new perspectives and behaviours. We will use this information to further shape our strategy and ensure that our products, services, and messaging resonates with our customer base and brings end users into a relationship development funnel.
Outlook
We have delivered strong revenue and operational performance in the first half of 2022, which, alongside new product launches and the building of a robust strategic growth plan, we believe will significantly support our customer base in meeting their health needs. Through clear decision making and proactive routes to self-selection, we can add value to the customer journey. We are filled with optimism and energy for the remainder of the year, where we will see our commercial, digital and product teams continue to strengthen, and deliver the builds and rollout plans that will underpin further growth.
Our half year and post-period performance has further demonstrated the establishment of a strong, credible, commercially focused operation that is committed to growth and delivery, and our excitement for next year is further heightened by the fact that we are still in the relatively early stages of our growth plan, which is anchored within at-home testing. Our Management and Board firmly believe in MyHealthChecked and are committed to building further upon this position of strength that has been achieved, so far, in 2022.
Adam Reynolds Penny McCormick Chairman Chief Executive Officer 21 September 2022
Consolidated statement of comprehensive income
For the 6 months ended 30 June 2022
Unaudited Unaudited 6 months Audited 6 months ended ended Year ended 30 June 30 June 31 December 2022 2021 2021 Notes GBP'000 GBP'000 GBP'000 ----------------------------- ------ ---------------- ------------ ------------- Revenue 3 9,832 3,274 16,376 Cost of sales (8,321) (2,174) (11,251) Gross profit 1,511 1,100 5,125 Other administrative expenses (1,395) (1,360) (2,553) Impairment of intangible assets - - (414) Share-based payments (104) (7) (112) ----------------------------- ------ ---------------- ------------ ------------- Administrative expenses (1,499) (1,367) (3,079) ----------------------------- ------ ---------------- ------------ ------------- Operating profit/(loss) 12 (267) 2,046 Finance expenses (3) (2) (2) Additional consideration payable on the acquisition of The Genome Store Limited - - (40) Contingent consideration on the acquisition of Nell Health Limited no longer payable 1,000 - - ----------------------------- ------ ---------------- ------------ ------------- Profit/(loss) before income tax 1,009 (269) 2,004 Tax - - - Profit/(loss) for the period 3 1,009 (269) 2,004 ----------------------------- ------ ---------------- ------------ ------------- Attributable to owners of the parent: 1,009 (269) 2,004 Earnings/(loss) per ordinary share - basic 4 0.13p (0.04p) 0.28p Fully diluted earnings per ordinary share 4 0.13p - 0.27p
Consolidated statement of financial position
As at 30 June 2022
Unaudited Unaudited Audited 30 June 30 June 31 December 2022 2021 2021 Notes GBP'000 GBP'000 GBP'000 ----------------------------- ------ ---------- ---------- ------------- Non-current assets Property, plant and equipment 88 152 163 Right-of-use assets 88 - - Intangible assets 2,520 590 2,289 Total non-current assets 2,696 742 2,452 ----------------------------- ------ ---------- ---------- ------------- Current assets Inventories 711 783 497 Trade and other receivables 3,224 3,114 2,332 Cash and cash equivalents 6,995 2,214 6,387 ----------------------------- ------ ---------- ---------- ------------- Total current assets 10,930 6,111 9,216 ----------------------------- ------ ---------- ---------- ------------- Total assets 13,626 6,853 11,668 ----------------------------- ------ ---------- ---------- ------------- Current liabilities Trade and other payables 5,094 2,994 3,315 Lease liabilities 26 - - Deferred taxation - 87 - Deferred consideration and other provisions - 226 1,240 Total current liabilities 5,120 3,307 4,555 ----------------------------- ------ ---------- ---------- ------------- Non-Current liabilities Lease liabilities 40 - - Total non-current
liabilities 40 - - ----------------------------- ------ ---------- ---------- ------------- Total liabilities 5,160 3,307 4,555 ----------------------------- ------ ---------- ---------- ------------- Net assets 8,466 3,546 7,113 ----------------------------- ------ ---------- ---------- ------------- Share capital 5 780 725 756 Deferred shares 6,359 6,359 6,359 Share premium account 16,887 15,513 16,671 Capital redemption reserve 1,815 1,815 1,815 Reverse acquisition reserve (6,044) (6,044) (6,044) Retained earnings (11,331) (15,745) (12,444) Share-based payment reserve - 923 - Total equity 8,466 3,546 7,113 ----------------------------- ------ ---------- ---------- -------------
Consolidated statement of changes in equity
For the 6 months ended 30 June 2022
Share-based Capital Reverse Share Deferred Share payment redemption acquisition Retained capital shares Premium reserve reserve reserve earnings Total GBP '000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 --------------- --------- ----------- ---------- ------------ ------------- ------------- ----------- -------- Equity as at 1 January 2021 518 6,359 12,442 916 1,815 (6,044) (15,476) 530 Profit for the year - - - - - - 2,004 2,004 --------------- --------- ----------- ---------- ------------ ------------- ------------- ----------- -------- Total comprehensive profit - - - - - - 2,004 2,004 Transfer from share- based payment reserve - - - (916) - - 916 - Issue of shares net of expenses 194 - 2,979 - - - - 3,173 Conversion of loan note and interest 13 92 - - - - 105 Exercise of options 2 - 18 - - - - 20 Other share issue 1 16 - - - - 17 Share-based payments - - - - - - 112 112 Acquisition of Nell Health Limited 28 1,124 - - - - 1,152 --------- ----------- ---------- ------------ ------------- ------------- ----------- -------- Equity as at 31 December 2021 756 6,359 16,671 - 1,815 (6,044) (12,444) 7,113 Profit for the period - - - - - - 1,009 1,009 --------------- --------- ----------- ---------- ------------ ------------- ------------- ----------- -------- Total comprehensive profit - - - - - - 1,009 1,009 Share-based payments - - - - - - 104 104 The Genome Store deferred consideration 24 - 216 - - - - 240 Equity as at 30 June 2022 780 6,359 16,887 - 1,815 (6,044) (11,331) 8,466 --------------- --------- ----------- ---------- ------------ ------------- ------------- ----------- --------
Consolidated statement of cash flows
For the 6 months ended 30 June 2022
Unaudited Unaudited 6 months ended 6 months ended Audited 30 June 30 June Year ended 2022 2021 31 December 2021 GBP'000 GBP'000 GBP'000 ---------------- ----------------- ------------------ Cash flows from operating activities Profit/(loss) before taxation 1,009 (269) 2,004 Adjustments for: Deferred consideration adjustment (1,000) - 40 Decrease in provisions - - (26) Depreciation and amortization 169 61 157 Impairment of intangible assets - - 414 Finance expenses 3 2 2 Share-based payments 104 7 112 Adjusted operating profit/(loss) before changes in working capital 285 (199) 2,703 Changes in working capital Increase in inventory (214) (781) (494) Increase in trade and other receivables (892) (2,918) (2,124) Increase in trade and other payables 1,779 2,610 2,931 Cash generated/(used) in operations 958 (1,288) 3,016 Other interest paid (3) (2) (2) Net cash inflow/(outflow) from operating activities 955 (1,290) 3,014 ---------------------------------------------------------- ---------------- ----------------- ------------------ Investing activities Purchase of property, plant and equipment (117) (128) (147) Purchase of intangible assets (296) (3) (102) Acquisition of Nell Health Limited - - (50) Net cash flows used in investing activities (413) (131) (299) ---------------------------------------------------------- ---------------- ----------------- ------------------ Financing activities Issue of ordinary shares (net of issue expenses) - 3,174 3,211 New lease finance 100 - - Repayment of lease liability (34) (5) (5) ---------------------------------------------------------- ---------------- ----------------- ------------------ Net cash inflows from financing activities 66 3,169 3,206 ---------------------------------------------------------- ---------------- ----------------- ------------------ Net change in cash and cash equivalents 608 1,748 5,921 Cash and cash equivalents at the beginning of the period 6,387 466 466 ---------------------------------------------------------- ---------------- ----------------- ------------------ Cash and cash equivalents at the end of the period 6,995 2,214 6,387 ---------------------------------------------------------- ---------------- ----------------- ------------------
Notes to the unaudited interim financial information for the 6 months ended 30 June 2022
1. General information
MyHealthChecked PLC is a public limited company incorporated and domiciled in England and Wales. The registered office of the Company is The Maltings, East Tyndall Street, Cardiff, CF24 5EA. The registered company number is 06573154.
The principal activity of the Group is in the development and commercialisation of at-home health diagnostics medical tests.
2. Significant accounting policies
Basis of preparation
The interim financial information for the six months ended 30 June 2022, which was approved by the Board of Directors on 20 September 2022, does not constitute statutory accounts as defined by section 434 of the Companies Act 2006.
These interim consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements.
The financial information presented is unaudited and has been prepared using the same accounting policies as those adopted in the financial statements for the year ended 31 December 2021 and expected to be adopted in the financial year ending 31 December 2022.
The interim financial information includes unaudited comparative figures for the unaudited 6 months to 30 June 2021 and comparatives for the year ended 31 December 2021 that have been extracted from the audited financial statements for that year.
The financial statements for the year ended 31 December 2021 were reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditors was unqualified and did not contain an adverse statement under section 498 (2) or (3) of the Companies Act 2006.
In the opinion of the Directors, the interim financial information for the period presents fairly the financial position and the results from operations and cash flows for the period.
Going concern
The interim financial statements have been prepared under the going concern basis as the Directors have undertaken a review of the future financing requirements of the ongoing operation of the business and considers the Group is able to meet its working capital requirements.
3. Segment information
In the opinion of the directors, the Group has one class of business, being that of the provision of diagnostic healthcare products. All the segment assets associated with the provision of diagnostic healthcare products are located in the UK.
Unaudited Unaudited Audited 30 June 2022 30 June 2021 31 December 2021 GBP'000 GBP'000 GBP'000 ------------------------------------------------------------------ -------------- -------------- ------------------ Revenue from the provision of diagnostic healthcare products 9,832 3,274 16,376 ------------------------------------------------------------------ -------------- -------------- ------------------ Profit for the period from provision of diagnostic healthcare products 430 131 2,815 Corporate costs (421) (400) (771) Deferred consideration adjustment 1,000 - (40) ------------------------------------------------------------------ -------------- -------------- ------------------ Group profit/(loss) before and after tax 1,009 (269) 2,004 ------------------------------------------------------------------ -------------- -------------- ------------------ Cash 6,995 2,214 6,387 Segment assets 6,579 4,543 5,221 Corporate assets 52 96 60 ------------------------------------------------------------------ -------------- -------------- ------------------ Total assets 13,626 6,853 11,668 ------------------------------------------------------------------ -------------- -------------- ------------------ Segment liabilities 4,973 3,070 3,057 Corporate liabilities 187 237 1,498 ------------------------------------------------------------------ -------------- -------------- ------------------ Total liabilities 5,160 3,307 4,555 ------------------------------------------------------------------ -------------- -------------- ------------------ 4. Profit/(loss) per share Unaudited Unaudited Audited 30 June 2022 30 June 2021 31 December 2021 Basic and diluted Profit/(loss) for the period GBP1,009,000 GBP(269,000) GBP2,004,000 Weighted average number of shares - basic 774,420,000 665,654,000 710,852,000 Weighted average number of shares - fully diluted 797,488,000 - 744,056,000 Profit/(loss) per share 0.13p (0.04)p 0.28p Fully diluted profit per share 0.13p - 0.27p --------------------------------------------------- -------------- -------------- ------------------
Basic profit/(loss) per share is calculated by dividing the profit/(loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period. Due to the loss in the six month period ended 30 June 2021 the effect of the share options was considered anti-dilutive and hence no diluted loss per share information has been provided.
5. Share capital
On 22 February 2021, 194,285,714 ordinary shares were at issued at 1.75p per share for a total consideration of GBP3.4 million before expenses of GBP227,000 and the convertible loan note (plus accrued interest) was converted into 13,138,647 shares at an issue price of 0.8p per share. On the acquisition of Nell Heath Limited on 3 July 2021 a further 27,842,931 new ordinary shares of 0.1p each were issued at 4.14p per share as part of the initial consideration payable of GBP1.2m. In addition, 2,500,000 EMI options were exercised during the year at a price of 0.8p per share and 500,000 shares were issued to Ms McCormick at a price of 3.5p in part settlement of her performance related pay.
On 25 March 2022, 24,000,000 new ordinary shares of 0.1p were issued to settle the deferred consideration payable on the acquisition of The Genome Store Limited of GBP240,000 after all performance milestones were met.
This interim financial statement will be released in accordance with the AIM Rules for Companies, available shortly on the Company's website at https://investors.myhealthchecked.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR DBLFLLKLBBBZ
(END) Dow Jones Newswires
September 21, 2022 02:00 ET (06:00 GMT)
1 Year Concepta Chart |
1 Month Concepta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions